Seroatlas · Human Serome Atlas

FBLL1

RNA 2'-O-methyltransferase FBLL1

Also known as: FBLL1_HUMAN, LOC345630

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: A6NHQ2
Gene: FBLL1
Ensembl: ENSG00000188573
Chromosome: 5
Canonical length: 334 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nucleoli fibrillar center

OverviewNCBI Gene

Predicted to enable RNA binding activity; histone H2A Q104 methyltransferase activity; and rRNA methyltransferase activity. Predicted to be involved in box C/D sno(s)RNA 3'-end processing and rRNA methylation. Predicted to act upstream of or within blastocyst hatching. Located in fibrillar center and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

334 residues, UniProt reviewed canonical sequence.

>A6NHQ2|FBLL1
     1  MKSAASSRGG GGGGRGGGGW GSWGGGRGGG GGAGKGGGGD GGGQGGKGGF GARARGFGGG
    61  GRGRGRGGGD GKDRGGGGQR RGGVAKSKSR RRKGAMVVSV EPHRHEGVFI YRGAEDALVT
   121  LNMVPGQSVY GERRVTVTEG GVKQEYRTWN PFRSKLAAAI LGGVDQIHIK PKSKVLYLGA
   181  ASGTTVSHVS DIIGPDGLVY AVEFSHRAGR DLVNVAKKRT NIIPVLEDAR HPLKYRMLIG
   241  MVDVIFADVA QPDQSRIVAL NAHTFLRNGG HFLISIKANC IDSTASAEAV FASEVRKLQQ
   301  ENLKPQEQLT LEPYERDHAV VVGVYRPLPK SSSK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FBLL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 41 nTPM

Expression across tissuesHPA

Tissue

hypothalamus: 41 nTPM
cerebral cortex: 36 nTPM
hippocampal formation: 25 nTPM
cerebellum: 24 nTPM
amygdala: 23 nTPM
basal ganglia: 23 nTPM

Single-cell type

adrenal medulla cells: 32 nCPM
pancreatic islet cells: 15 nCPM
other brain neurons: 14 nCPM
brain inhibitory neurons: 8.9 nCPM
brain excitatory neurons: 7.8 nCPM
thyrotrophs: 7.3 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hypothalamus: 61 nTPM
cerebral cortex: 51 nTPM
pons: 49 nTPM
basal ganglia: 39 nTPM
midbrain: 38 nTPM
medulla oblongata: 37 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.36
gnomAD pLI: 0.09
gnomAD missense Z: 1.4

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FBLL1 as an antibody target. Whether an autoantibody or antibody against FBLL1 could matter depends on whether native FBLL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FBLL1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label FBLL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...